Physician profile
Donald E Penn
NPI 1780628388
$4,931.16
in general payments reported to CMS, 2019-2025
28 companies · $1,000 in 2025
The $1,000 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $396 · 2020: $267 · 2021: $582 · 2022: $555 · 2023: $973 · 2024: $1,158 · 2025: $1,000.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,100 · Education: $30.40.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,100.28 |
| Education | $30.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,188.13 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $566.11 | 2019-2025 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $484.66 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $476.87 | 2020-2025 | Stelara, Simponi Aria, Simponi |
| Merck Sharp & Dohme LLC | $189.89 | 2019-2023 | Dificid, Zinplava |
| Celgene Corporation | $169.62 | 2021-2024 | Zeposia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.60 | 2023-2024 | Cyltezo |
| Mauna Kea Technologies, INC. | $98.90 | 2019 | |
| Boston Scientific Corporation | $77.79 | 2019 | |
| Lilly USA, LLC | $71.39 | 2024-2025 | Omvoh |
| Gilead Sciences, INC. | $69.27 | 2021-2025 | |
| Ardelyx, INC. | $61.00 | 2024-2025 | Ibsrela |
| Amgen INC. | $52.76 | 2023 | Avsola, Amjevita |
| Phathom Pharmaceuticals, INC. | $51.75 | 2024-2025 | Voquezna |
| Ironwood Pharmaceuticals, INC | $49.06 | 2021-2024 | Linzess |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $31.95 | 2019 | |
| Pfizer INC. | $30.40 | 2024 | |
| Organon LLC | $21.07 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $18.13 | 2024 | Iqirvo |
| Sandoz INC. | $17.26 | 2024 | Hyrimoz |
| Orphalan INC | $16.33 | 2024 | Cuvrior |
| Regeneron Healthcare Solutions, INC. | $13.60 | 2022 | |
| Braintree Laboratories, INC. | $13.51 | 2024 | Suflave, Sutab |
| Nestle Healthcare Nutrition INC. | $12.73 | 2023 | |
| W. L. Gore & Associates, INC. | $12.25 | 2020 | |
| Alfasigma USA, INC. | $12.00 | 2020 | |
| Echosens North America, INC. | $11.13 | 2025 | Fibroscan |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$19,987.16 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donald Penn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.